• 5 min read
• Published on 25 July 2025
Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
View the full Basket:Next-Gen Multiple Myeloma Treatments
Let’s be honest, the world of biotechnology investing can feel like a casino. Every other week, it seems, there’s a new ‘miracle cure’ that promises to change the world, only to fizzle out in a clinical trial, taking a mountain of investor cash with it. I’ve seen it all before. So, when I hear about a ‘revolution’ in cancer treatment, my cynical eyebrow tends to arch so high it nearly leaves my forehead. But just occasionally, something comes along that cuts through the noise. Right now, that something is happening in the fight against a blood cancer called multiple myeloma.
View the full Basket:Next-Gen Multiple Myeloma Treatments
Multiple myeloma isn't exactly a household name, but it’s the second most common blood cancer out there. For years, the treatment path was grim and predictable. Now, that’s changing, and changing fast. The reason for my cautious optimism is a new class of drugs, specifically something called bispecific antibodies, which have recently been given the nod by the American regulators at the FDA.
Think of it this way. For decades, we’ve been carpet bombing cancer with chemotherapy, hoping to kill the bad cells without doing too much damage to the good ones. These new immunotherapies are different. They are more like guided missiles. They essentially grab one of your body’s own immune cells, a T cell, and physically drag it over to a cancer cell, forcing an introduction. The result is a highly targeted attack, turning your own immune system into a precision weapon. It’s clever, it’s elegant, and for patients who had run out of options, it can be life-altering.
View the full Basket:Next-Gen Multiple Myeloma Treatments
When a genuine breakthrough happens, you can be sure the pharmaceutical giants will not be far behind. It’s a high stakes game, and the main players are already at the table. Regeneron is one of the pioneers here, validating the whole approach with its recent approval. Then you have the behemoth, Johnson & Johnson, which is hedging its bets with two different but related technologies. And of course, Pfizer, never one to miss a party, has muscled its way in by acquiring another company to get its hands on a promising drug.
What this tells me is that the industry’s biggest brains and deepest pockets believe this is more than just a flash in the pan. They are pouring billions into this space because the market is substantial. These are not cheap treatments, but when you are offering patients years of extra life, healthcare systems are often prepared to pay premium prices. This creates a powerful revenue stream, but it also fuels intense competition, which in turn drives even faster innovation.
View the full Basket:Next-Gen Multiple Myeloma Treatments
Now, before you get carried away, let’s pour a little cold water on the excitement. Investing in this sector is not for the faint of heart. For every successful drug, there is a graveyard of expensive failures. Clinical trials can and do go wrong, regulators can be unpredictable, and a competitor can always swoop in with a slightly better product. The potential rewards are high, but let’s not pretend the risks aren’t just as significant.
To me, the most sensible way to think about this is not by betting on a single horse, but by looking at the entire field. The companies leading this charge, from the focused innovators to the diversified giants, form a compelling theme. You can see this collection of firms in the Next-Gen Multiple Myeloma Treatments basket, which groups these key players together. This approach acknowledges that the entire category is advancing, even if individual company fortunes may rise and fall. The technology itself, this ability to harness the immune system, has applications that could stretch far beyond just one type of cancer, which is where the long term story might get truly interesting.
View the full Basket:Next-Gen Multiple Myeloma Treatments
View the full Basket:Next-Gen Multiple Myeloma Treatments
View the full Basket:Next-Gen Multiple Myeloma Treatments
View the full Basket:Next-Gen Multiple Myeloma Treatments
View the full Basket:Next-Gen Multiple Myeloma Treatments
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
View the full Basket:Next-Gen Multiple Myeloma Treatments
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article